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Background: Previous studies including our group have indicated the effects of ezetimibe on increased plasma
proprotein convertase subtilisin/kexin type 9 (PCSK9) concentration, while the rapid expression in different organs
and the potential molecular mechanisms for this impact have not been carefully evaluated.
Methods: Thirty rats were randomly divided into two groups (n = 15 for each), which were orally administrated
with ezetimibe (10 mg/kg/day) or normal saline. Blood samples were obtained at day 3 after orally administration,
and the PCSK9 levels were determined by ELISA. We further analyzed the mRNA expression of PCSK9, low-density
lipoprotein receptor (LDLR), sterol regulator element-binding protein 2 (SREBP2), and hepatocyte nuclear factor 1
alpha (HNF-1α) by real-time PCR, as well as the protein expression by western blot, in liver, intestine and kidney
respectively.
Results: Ezetimibe significantly increased plasma PCSK9 levels compared with control group, while there was no
significant difference between the two groups with regard to lipid profile at day 3. Moreover, ezetimibe remarkably
increased the expression of PCSK9, LDLR, SREBP2 and HNF-1α in liver. Enhanced expression of PCSK9, LDLR and
SREBP2 protein were found in intestine and kidney, while no changes in the expression of HNF-1α were observed
in intestine and kidney of rats with ezetimibe treatment.
Conclusions: The data demonstrated that ezetimibe increased PCSK9 expression through the SREBP2 and HNF-1α
pathways in different organs, subsequently resulting in elevated plasma PCSK9 levels prior to the alterations of lipid
profile in rats.
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Proprotein convertase subtilisin/kexin type 9 (PSCK9) is
a circulating protein synthesized mainly in the liver, intes-
tine, kidney and brain,which impairs low-density lipopro-
tein (LDL) clearance by binding directly to the epidermal
growth factor repeat A of the LDL receptor (LDLR) and
subsequently targeting it for degradation [1-4]. This
process, subsequently, results in increased LDL-cholesterol
(LDL-C) levels in the circulation [5,6]. Recent advances
have indicated that statins (HMG-CoA redictase inhibitor)* Correspondence: lijianjun938@126.com
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unless otherwise stated.could eventually up-regulate PCSK9 levels in human by
increasing the activity of sterol regulator element-binding
protein 2 (SREBP2), which is a transcription factor that ac-
tivates both LDLR and PCSK9 gene [7-10]. In addition,
another common prescribed lipid-lowering drug, ezeti-
mibe (an inhibitor of intestine cholesterol absorption) is
widely used for the treatment of dyslipidemia, which could
decrease LDL-C by approximately 20% when administered
alone and when combined with statin could achieve 15%
more decrease in LDL-C concentrations compared with
statin alone [11]. However, limited data are currently avail-
able regarding the impact of ezetimibe on PCSK9 expres-
sion, especially in different candidate organs except for the
liver. More importantly, the potential molecular pathways
involved in PCSK9 expressions have less been investigated.is an Open Access article distributed under the terms of the Creative Commons
rg/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 The sequences of primers for Real-Time PCR used
in the study











PCR: polymerase chain reaction; F: forward; R: reverse; LDLR: low density
lipoprotein receptor; PCSK9: proprotein convertase subtilisin/kexin type 9;
SREBP2: sterol regulatory element binding protein-2; HNF-1α: Hepatocyte
Nuclear Factor 1 alpha; GAPDH: glyceraldehyde-phosphate dehydrogenase.
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rapid increase of plasma PCSK9 concentration prior to
the decrease of LDL-C levels in rats, even after 3 days of
administration [12]. Hence, the aim of the present study
was to investigate (1) the rapid impacts of ezetimibe on
PCSK9 expression in different organs; (2) the underlying
mechanisms for the elevated plasma PCSK9 levels after
ezetimibe treatment using this 3-days’ rat model.
Materials and methods
Materials
CircuLex rat PCSK9 enzyme-linked immunosorbent assay
(ELISA) kit was purchased from CycLex Co., Nagano,
Japan. The antibodies of PCSK9, LDLR and SREBP2 were
purchased from Abcam Inc., Cambridge, MA, USA. The
anti-hepatocyte nuclear factor-1 alpha (HNF-1α) was ob-
tained from Santa Cruz Biotechnology Inc., Santa Cruz,
CA, USA. Glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) and horseradish peroxidase-conjugated second-
ary antibody were purchased from Cell Signal Technology
Inc., Beverly, MA, USA.
Animal experimental design
Male Sprague–Dawley rats (weighing 180–220 g) were
fed in a temperature-conditioned (22-24°C) room with
alternating 12 h light/dark cycles and free access to food
and water for 3 days to get familiar with the environ-
ment. At the start of the study, 30 rats were randomly
assigned to two groups: (1) control group (n = 15, orally
administrated with normal saline), (2) ezetimibe group
(n = 15, orally administrated with ezetimibe 10 mg/kg/
day). After 3 days’ orally administration, all rats were
anaesthetized with pentobarbital sodium (40 mg/kg) via
intraperitoneal injection and 2 ml fasting blood were
collected from the inferior vena cava and transferred to
K2 EDTA tubes. The blood samples were centrifuged,
and the plasma was stored at −80°C until the analyses
were performed. Immediately after blood sampling, livers,
small intestines and kidneys were then removed and rap-
idly stored in liquid nitrogen for RNA and protein analysis.
All experimental procedures and protocols were approved
by the Care of Experimental Animals Committee of FuWai
Hospital, Chinese Academy of Medical Sciences and
Peking Union Medical College.
Assay of plasma PCSK9 and lipid profile concentrations
Concentrations of total cholesterol (TC), triglycerides
(TG), high density lipoprotein cholesterol (HDL-C) and
LDL-C were determined on an automatic biochemistry
analyzer (Hitachi 7150, Tokyo, Japan). Plasma PCSK9 con-
centrations were measured using a high sensitivity, quanti-
tative sandwich enzyme immunoassay. The lower limit of
detection was 0.038 ng/ml.Detection of PCSK9, LDLR, SREBP2 and HNF-1α mRNA
expression in liver, intestine and kidney
Key enzymes of lipid metabolism, which were analyzed
by real-time quantitative polymerase chain reaction (RT-
PCR), were selected as candidate genes for the assessment
of their mRNA expression levels in the liver, intestine and
kidney of rats studied (Table 1). Briefly, total RNA in all
tissue was isolated from hepatic tissue using the Trizol re-
agent Kit (Invitrogen, USA) following the manufacture’s
instructions. And then, it was measured by spectropho-
tometry at an absorbance of 260 nm, and designated the
purity valid if the ratio of A260/A280 was in the range
from 1.8 to 2.0. The integrity of the RNA was checked
by denaturing agarose gel electrophoresis and ethidium
bromide staining. 3 μg of the total RNA was reversed tran-
scribed by reverse Aid First Strand cDNA synthesis kit
(Fermentas, CA, USA). The abundances of key genes
(PCSK9, LDLR, SREBP-2 and HNF-1α) and GAPDH mRNA
were analyzed by RT-PCR using the 7500HT RT-PCR sys-
tem (Applied Biosystems, Foster, CA, USA). RT-PCR was
performed using the SYBR Premix ExTaq (TaKaRa Bio
Inc. Japan) according to the manufacturer’s instructions.
Standard curves for each primer pair were generated by
serial dilutions of cDNA from a reference sample and used
for regression analyses. All PCR assays were performed in
triplicate. The variance of the triplicate measurements
was <1%. Results were analyzed using the standard curve
method by the sequence detection systems software. The
data was expressed as the relative levels of mRNA after
normalized with GAPDH.
Western blot analysis of PCSK9, LDLR, SREBP2 and
HNF-1α protein expression
Western blot analysis of total protein was performed as
previously described [13,14]. Approximately 150 mg of
Figure 1 The comparison of plasma PCSK9 levels in rats
between control and ezetimibe groups. *p < 0.05, compared with
control group.
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tract protein for each assay respectively. Primary anti-
bodies for anti-LDLR and anti-PCSK9 were used at a
dilution of 1:1000, and primary antibodies for anti-SREBP2
and anti-HNF-1α were used at a dilution of 1:200. All sec-
ondary antibodies were used at a dilution of 1:2000. Pro-
tein bands were visualized by the ChemiDoc XRS system
and the density was analyzed using the Quantity one soft-
ware (Bio-Rad, USA).
Statistical analysis
Data are expressed as mean ± standard deviation (SD).
Comparisons between two groups were evaluated by
using unpaired two-tailed t-test. A value of p < 0.05 was
considered statistical significance. SPSS 19.0 statistical
software package (SPSS Inc., Chicago, IL, USA) was used
for all of the statistical analysis.
Results
Rapid effects of ezetimibe on plasma PCSK9
concentrations
Table 1 showed the sequences of primers for Real-Time
PCR used in the study. As shown in Table 2, there was no
significant difference in lipid parameters between control
and ezetimibe groups at day 3 (p > 0.05). While in rats re-
ceiving ezetimibe 10 mg/kg/day treatment for 3 days,
plasma PCSK9 levels significantly increased compared with
control group (661.37 ± 298.56 ng/ml vs. 289.36 ± 109.51
ng/ml, p < 0.05) (Table 2 and Figure 1).
Changes of PCSK9, LDLR, SREBP2 and HNF-1α mRNA
expression after ezetimibe treatment
Relative mRNA expression of PCSK9, LDLR, SREBP2
and HNF-1α mRNA were determined in liver, intestine
and kidney. As a result, the PCSK9, LDLR, SREBP2 and
HNF-1α mRNA expression in liver of rats with ezeti-
mibe treatment increased 3.6-fold, 2.1-fold, 2-fold and
1.9-fold respectively (p < 0.001 or p < 0.01, respectively)
compared to the control group (Figure 2A-D). Moreover,Table 2 The laboratory data of plasma PCSK9 levels and
lipid profile in rats
Parameters Group
Control (n = 15) Ezetimibe (n = 15)
PCSK9 (ng/ml) 289.36 ± 109.51 661.37 ± 298.56*
TG (mmol/L) 0.75 ± 0.68 0.59 ± 0.46
TC (mmol/L) 2.15 ± 0.23 2.13 ± 0.37
LDL-C (mmol/L) 0.54 ± 0.15 0.52 ± 0.13
HDL-C (mmol/L) 1.12 ± 0.30 1.21 ± 0.26
Data are expressed as mean ± SD. *p < 0.05, compared with control group.
PCSK9: proprotein convertase subtilisin/kexin type 9; TG: triglycerides; TC: total
cholesterol; LDL-C: low density lipoprotein cholesterol; HDL-C: high density
lipoprotein cholesterol.the expression of PCSK9, LDLR and SREBP2 mRNA was
significantly increased in both intestine and kidney after
3 days of ezetimibe treatment (all p < 0.05, Figure 2A-C).
However, in the present study, no changes of the HNF-1α
mRNA expression were found in intestine and kidney in
ezetimibe group compared with the control group (all p >
0.05, Figure 2D).Effects of ezetimibe on PCSK9, LDLR, SREBP2 and HNF-1α
protein expression
The effects of ezetimibe 10 mg/kg/day treatment for
3 days on PCSK9, LDLR, SREBP2 and HNF-1α protein
levels were also investigated in the present study. As
shown in Figure 3, ezetimibe could remarkably enhance
the protein expressions of PCSK9, LDLR, SREBP2 and
HNF-1α in liver. Interestingly, the increased expression
of PCSK9, LDLR and SREBP2 protein were found in in-
testine and kidney, while no changes in the expression
of HNF-1α were observed in intestine and kidney of rats
with ezetimibe treatment compared with the control
group.Discussion
The impact of ezetimibe on circulating PCSK9 concen-
tration and related mechanism has less been studied. In
the present study, we confirmed that ezetimibe could
rapidly increase the plasma PCSK9 concentration prior
to the changes of lipid profile in rats. The main finding
of this study is that ezetimibe could significantly increase
the expression of PSCK9, LDLR, SREBP2 and HNF-1α in
liver, intestine and kidney, but the expression of HNF-1α
in liver alone in rats with ezetimibe 10 mg/kg/day after
3 days of treatment. Therefore, the present study may pro-
vide important novel findings including: 1) ezetimibe en-
hances the expression of PCSK9 through the multiple
organ’s manner in rats; 2) SREBP2 pathway was involved
in increased PCSK9 expression in all defined PCSK9-
Figure 2 The expression of PCSK9, LDLR, SREBP2 and HNF-1α mRNA analyzed by real-time PCR in liver, intestine and kidney respectively.
After ezetimibe treatment for 3 days, the mRNA expression of PCSK9 (A), LDLR (B), and SREBP2 (C) increased significantly in all organs compared
with control group, while the expression of HNF-1α mRNA increased markedly only in liver (D). Data are the mean ± SD. *p < 0.05, **p < 0.01,
***p < 0.001, compared with control group.
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a contributor for increased PCSK9 in liver alone.
PCSK9, which has a central role on cholesterol homeo-
stasis by enhancing the endosomal and lysosomal degrad-
ation of hepatic LDLR, is closely related to lipid metabolism
[15-17]. Therefore, PCSK9 has been considered as an im-
portant novel target for controlling dyslipidemia [18]. Pre-
vious studies have indicated that PCSK9 promotes the
degradation of LDLR and can limit the beneficial effects of
lipid-lowering drugs [19-21]. Multiple observations sug-
gested that lipid-lowering drugs could elevate plasma
PCSK9 concentrations [21,22] and might have rapid im-
pact on PCSK9 levels [23]. Ezetimibe, an inhibitor of in-
testine cholesterol absorption, can decrease cholesterol
synthesis and reduce circulating LDL-C concentration
whenever it is prescribed alone or in combination with
statins in controlling dyslipidemia [24,25]. Recently, sev-
eral researchers have described that ezetimibe or the com-
bination of ezetimibe and statin stimulates the expression
of PCSK9 [12,26]. A study from Davignon J et al. reported
that patients treated with statins alone had a 45% increase
in PCSK9 levels and those treated with statin plus ezeti-
mibe showed an approximately 77% increase in PCSK9
concentrations [27]. Hentze H et al. [28] indicated that
plasma PCSK9 levels were increased by 137% in dyslipid-
emic cynomolgus monkeys after ezetimibe 14 days’ treat-
ment accompanied with LDL-C decrease by 58%. A
recent study from our group [12] demonstrated that the
PCSK9 levels increased by 124% in rats administrated withezetimibe 10 mg/kg/day for 3 days. Absolutely, these stud-
ies strongly suggested that ezetimibe could increase circu-
lating PCSK9 concentrations in a rapid manner.
It has been reported that PCSK9 could be expressed in
several organs, such as liver, intestine, brain and kidney
[29-32]. Interestingly, Turpeinen H et al. [33] and Chen
YQ et al. [34] reported that PCSK9 protein could be de-
tected in coronary atherosclerotic plaque and even in
cerebrospinal fluid. However, limited data are available
regarding the impact of ezetimibe on PCSK9 expression,
especially in different organs. Galman C et al. demon-
strated that ezetimibe treatment reduced cholesterol ab-
sorption, while the expression of hepatic PCSK9 mRNA
was unaltered in aged rats [35]. A recent study investigated
the impacts of ezetimibe 10 mg per day and simvastatin
40 mg per day, alone and in combination (ezetimibe 10 mg
per day plus simvastatin 40 mg per day) therapy for 14 days
in 72 healthy men on PCSK9 using a single center,
randomized, open-label design [36]. They found that
ezetimibe did not increase circulating PCSK9 concentra-
tions while simvastatin did, whenever ezetimibe was ad-
ministered alone or in combination with simvastatin.
Gouni-Berthold et al. [25] indicated that ezetimibe had no
effect on the expression of PCSK9 and LDLR protein in
mononuclear blood cells from healthy men. Therefore,
further exploration of the effects of ezetimibe on PCSK9
and potential organs may be of great interest. Our study,
for the first time, indicated that ezetimibe up-regulated
PCSK9 mRNA and protein expressions in liver, intestine
Figure 3 The expression of PCSK9, LDLR, SREBP2 and HNF-1α proteins in liver, intestine and kidney respectively. Western blot showed
(A): in ezetimibe group, the expression of PSCK9, LDLR and SREBP2 increased significantly in all organs,while the expression of HNF-1α increased
markedly only in liver. Quantification analysis showed the expression of PCSK9 (B), LDLR (C), SREBP2 (D) and HNF-1α (E) in liver, intestine and
kidney, respectively. CON: control; EZE: Ezetimibe. Data are the mean ± SD. *p < 0.05, **p < 0.01, ***p < 0.001, compared with control group.
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3 days. The disparity for their trial in humans and our
study in rats regarding the effects of ezetimibe on plasma
PCSK9 level may be due to the subjects studied.
In addition, limited published studies investigated po-
tential mechanisms for the increased expression of PCSK9
stimulated by ezetimibe. Brandon Ason et al. [37] applied
qRT-PCR to analyze the expression of 361 genes involved
in hepatic lipid metabolism and found that many genes
within the SREBP-2 pathway were induced following eze-
timibe treatment (2.5-fold average induction relative to
control). This study provides theoretical evidences about
the impact of ezetimibe on plasma PCSK9 levels, that is,
the enhanced PCSK9 expression may be also associated
with SREBP-2 pathway. Several previous studies have indi-
cated that the impact of statins on PCSK9 expression was
mainly related to SREBP-2 pathway. Besides, Li H [38]et al. also showed that a coordinate reduction of nuclear
SREBP2 and HNF-1α by berberine led to a strong sup-
pression of PSCK9 transcription in HepG2 cells, indirectly
indicating a regulation of SREBP2 and HNF-1α on PCSK9.
In our study, data suggested that ezetimibe significantly
increased hepatic SREBP2 and HNF-1α expression, and
dramatically up-regulated the SREBP2 expression in intes-
tine and kidney. However, there were no significant differ-
ences in HNF-1α expression in intestine and kidney of
rats treated with ezetimibe compared to that of control
rats. Additionally, the reports by Telford DE et al. [26]
and Repa JJ et al. [39] demonstrated that ezetimibe could
enhance the expression of hepatic LDLR mRNA which
was increased by 1.7-fold in pigs and 2-fold in wild-type
mice, respectively, through SREBP2 pathway activation.
Consistent with previous studies, we found that ezetimibe
markedly increased the expression of LDLR and SREBP2
Xu et al. Journal of Translational Medicine  (2015) 13:87 Page 6 of 7in all organs of rats investigated in the present study. Add-
itionally, both PCSK9 and LDLR gene transcription are
under the control of SREBP2, which was activated by the
low intracellular cholesterol levels. Moreover, the intracel-
lular cholesterol levels were decreased more quickly than
the plasma after the lipid-lowering drug treatment [10].
Therefore, in the present study, the SREBP2 pathway was
dramatically stimulated even when the plasma cholesterol
concentration was not changed. Nonetheless, further stud-
ies are needed to observe the long-term effect of ezetimibe
on plasma PCSK9 and the role of different pathways of
different organs in the regulations of circulating PCSK9.
Conclusion
In this 3-days’ rat model with ezetimibe administration,
our data demonstrated that ezetimibe could enhance PCSK9
expression rapidly, subsequently resulting in elevated plasma
PCSK9 levels prior to the alterations of lipid profile, which
was through the SREBP2 and HNF-1α pathways in differ-
ent organs.
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